OverviewSuggest Edit

Carna Biosciences is a company engaged in drug discovery support as well as drug discovery and development. It provides drug discovery supporting products and services including kinase protein, profiling services, assay development, crystallography, cell-based assay services, etc. The company also identifies and develops medicines for the treatment of cancer and inflammatory diseases using its kinase drug discovery platform, QuickScout.
TypePublic
Founded2003
HQKobe, JP
Websitecarnabio.com

Latest Updates

Employees (est.) (Mar 2022)64(+2%)
Share Price (May 2022)$10.8
Cybersecurity ratingCMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Carna Biosciences

Kohichiro Yoshino

Kohichiro Yoshino

President and Chief Executive Officer Representative Director
Norio Aikawa

Norio Aikawa

Head of Drug Discovery and Support Business Head of IP and Legal Department Director
Masaaki Sawa

Masaaki Sawa

Chief Scientific Officer, Director
Emi Yamamoto

Emi Yamamoto

Chief Financial Officer, Director President of CarnaBio USA, Inc.
Atsuo Arita

Atsuo Arita

Outside Director
Tsuguo Ogasawara

Tsuguo Ogasawara

Outside Director
Show more

Carna Biosciences Office Locations

Carna Biosciences has offices in Kobe and Natick
Kobe, JP (HQ)
1-chōme-5-5 Minatojima Minamimachi, Chūō-ku
Natick, MA, US
209 W Central St #307
Show all (2)

Carna Biosciences Financials and Metrics

Carna Biosciences Revenue

USD

Market capitalization (12-May-2022)

142.6m

Closing stock price (12-May-2022)

10.8

Cash (31-Dec-2021)

3.8b

EV

(3.1b)
Carna Biosciences's current market capitalization is $142.6 m.
Annual
JPYFY, 2018FY, 2019FY, 2020FY, 2021

Cash

1.4b4.9b4.3b3.8b

Accounts Receivable

87.9m117.5m129.2m1.2b

Inventories

110.8m99.4m104.5m110.5m
Quarterly
JPYQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021Q3, 2021

Cash

1.2b1.3b4.6b5.2b4.9b4.7b3.7b3.2b3.8b

Accounts Receivable

101.0m2.2b185.9m108.2m91.0m91.2m98.1m73.9m64.9m

Inventories

105.5m103.7m104.5m89.2m91.8m99.0m112.2m110.6m109.8m
Annual
JPYFY, 2018FY, 2019FY, 2020FY, 2021

Net Income

(1.2b)913.1m(1.1b)(532.5m)

Depreciation and Amortization

12.7m9.4m12.4m19.2m

Inventories

7.2m11.4m(5.1m)(6.0m)

Accounts Payable

(2.5m)2.7m(1.7m)776.0k
Quarterly
JPYQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021Q3, 2021

Net Income

1.4b(396.3m)(780.8m)

Depreciation and Amortization

3.7m5.7m9.1m

Inventories

7.1m7.6m(6.1m)

Accounts Payable

3.0m(3.2m)(1.4m)
Show all financial metrics

Carna Biosciences Revenue Breakdown

Embed Graph

Carna Biosciences revenue breakdown by business segment: 44.1% from THE DRUG DISCOVERY SUPPORT and 55.9% from THE DRUG DISCOVERY

Carna Biosciences Cybersecurity Score

Cybersecurity ratingPremium dataset

C

79/100

SecurityScorecard logo

Carna Biosciences Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

Carna Biosciences Online and Social Media Presence

Embed Graph

Carna Biosciences News and Updates

Brickell Biotech Acquires Exclusive Global Rights to Portfolio of Novel STING Inhibitors Targeting Autoimmune and Inflammatory Diseases from Carna Biosciences

Lead STING inhibitor candidate, BBI-10, demonstrated dose-dependent cytokine reduction in nonclinical in vitro and in vivo studies providing strong proof-of-mechanism

Carna Biosciences Blogs

Two RET mutant kinases have been newly added to our lineup!

Two(2) RET mutant kinase products have been newly added to our lineup! Cat# 08-572 RET(G810C) Cat# 08-573 RET(G810R) Carna's Kinase Proteins are all produced 100% in-house and will assist your kinase drug discovery with its proven quali…

Chinese Website Released! 中文网站发布!

Carna's Services &Products website in Chinese has been released. Check it out from here! Carna的中文服务和产品网站已经发布。 从这里查看!

Carna Presented AS-1763 Posters at the 2022 American Association for Cancer Research (AACR) Annual Meeting

On April 11, 2022, Carna presented two posters highlighting the drug discovery and the result of the SAD part of Phase 1 study for BTK inhibitor AS-1763 at the American Association for Cancer Research (AACR) 2022 Annual Meeting in New Orleans, Louisiana.
Show more

Carna Biosciences Frequently Asked Questions

  • When was Carna Biosciences founded?

    Carna Biosciences was founded in 2003.

  • Who are Carna Biosciences key executives?

    Carna Biosciences's key executives are Kohichiro Yoshino, Norio Aikawa and Masaaki Sawa.

  • How many employees does Carna Biosciences have?

    Carna Biosciences has 64 employees.

  • Who are Carna Biosciences competitors?

    Competitors of Carna Biosciences include Jiangsu Hansoh Pharmaceutical Group, SK Biopharmaceuticals and Gracell.

  • Where is Carna Biosciences headquarters?

    Carna Biosciences headquarters is located at 1-chōme-5-5 Minatojima Minamimachi, Chūō-ku, Kobe.

  • Where are Carna Biosciences offices?

    Carna Biosciences has offices in Kobe and Natick.

  • How many offices does Carna Biosciences have?

    Carna Biosciences has 2 offices.